Current treatment options for neuroendocrine tumors

Area of Science:

• Oncology
• Endocrinology
• Nuclear Medicine

Background:

• Neuroendocrine tumors (NETs) exhibit diverse clinical behaviors, necessitating tailored therapeutic strategies.
• Treatment decisions for NETs depend on staging, grading, tumor origin, and peptide receptor expression.

Purpose of the Study:

• To review current and emerging therapeutic options for neuroendocrine tumors.
• To highlight advancements in managing NETs, focusing on personalized treatment approaches.

Main Methods:

• Review of existing literature on somatostatin analogues, chemotherapy, surgery, and local ablative therapies for NETs.
• Evaluation of peptide receptor radiotherapy (PRRT) and small-molecule inhibitors in NET treatment.
• Analysis of clinical studies demonstrating efficacy in progression-free and overall survival.

Main Results:

• Somatostatin analogues offer antisecretory and antiproliferative benefits.
• Chemotherapy is crucial for poorly differentiated NETs and effective in pancreatic and bronchial NETs.
• Surgery provides curative intent for localized NETs and debulking for advanced cases.
• Peptide receptor radiotherapy shows promise for prolonged survival in eligible patients.
• Small-molecule inhibitors targeting VEGF and mTOR pathways delay NET progression.

Conclusions:

• The therapeutic landscape for neuroendocrine tumors has significantly evolved, offering expanded options.
• Recent advancements, including PRRT and targeted therapies, have led to prolonged overall survival for NET patients.
• Personalized treatment strategies are key to optimizing outcomes in neuroendocrine tumor management.